Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051415 | 0.83 | MAPT (0.60) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL5215459 | 0.83 | RAB9A (0.55) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL5586004 | 0.80 | RAB9A (0.60) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL10367557 | 0.80 | MAPT (0.53) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL10367558 | 0.80 | MAPT (0.53) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL8027680 | 0.79 | MAPT (0.54) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL8027893 | 0.79 | SMN1; SMN2 (0.54) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL10365652 | 0.79 | MEN1 (0.57) | MAPTLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7869387 | 0.79 | KDM4E (0.53) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL2487385 | 0.77 | MAPT (0.66) | MAPTRAB9ALMNANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017060-B | A kind of purification process of disilicone hexachloride | 浙江博瑞电子科技有限公司 | 2019-06-28 | — | — | CN | claimed |
| CN-108017060-A | A kind of purification process of disilicone hexachloride | 浙江博瑞电子科技有限公司 | 2018-05-11 | — | — | CN | claimed |
| EP-2084163-B1 | TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2017-04-12 | — | — | EP | claimed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | claimed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | claimed |
| EP-1075483-B1 | HYGROMYCIN A DERIVATIVES | PFIZER PROD INC (US) | 2003-12-03 | — | — | EP | claimed |
| EP-1077984-B1 | 2\"-DEOXY HYGROMYCIN DERIVATIVES | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-6342497-B1 | 2″-deoxy hygromycin derivatives | PFIZER INC | 2002-01-29 | — | — | US | claimed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | claimed |
| EP-0445731-B1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER LAMBERT CO (US) | 1996-01-10 | — | — | EP | claimed |
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| EP-0138773-B1 | USE OF QUINOLINE DERIVATIVES FOR THE PROTECTION OF CROP PLANTS | CIBA-GEIGY AG (CH) | 1990-08-29 | — | — | EP | claimed |
| US-4749406-A | Quinoline derivatives and compositions thereof for the protection of cultivated plants | CIBA-GEIGY CORPORATION (US) | 1988-06-07 | — | — | US | claimed |
| US-4710508-A | ANALGESICS | WARNER-LAMBERT COMPANY (US) | 1987-12-01 | — | — | US | claimed |
| EP-0138773-A2 | Use of quinoline derivatives for the protection of crop plants | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | claimed |
| CN-108017060-B | A kind of purification process of disilicone hexachloride | 浙江博瑞电子科技有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-108017060-A | A kind of purification process of disilicone hexachloride | 浙江博瑞电子科技有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-4749406-A | Quinoline derivatives and compositions thereof for the protection of cultivated plants | CIBA-GEIGY CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
| US-4710508-A | ANALGESICS | WARNER-LAMBERT COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0138773-A2 | Use of quinoline derivatives for the protection of crop plants | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | MAPT 3084/4885RAB9A 3964/4885LMNA 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.